Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.
about
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerDevelopment of 99mTc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer.HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experienceRisk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis.T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.Trastuzumab and survival of patients with metastatic breast cancer.Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process.Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer.
P2860
Q27853134-92C08191-FB93-4653-A4E7-39261FB85709Q33649880-25FCBFF0-7E09-4500-B347-D7F3D2CB3E26Q34499609-3F080C13-E25E-41AB-A5E1-9BAA5F3F26FDQ35820575-0D8011A6-CA1E-4D92-8A18-31D4F0278196Q35915735-31AC915B-BA4E-4CEC-A187-3BB76D01ECFEQ37100311-C1129A5B-14BF-4565-9F1B-C7E4EFBA7FF1Q39178080-FD5E3738-A61D-49D9-BE91-E0E009DF6AF6Q39685521-5257D031-828A-45B5-B711-119F48509F25Q40159320-FEA25323-9216-4254-8C9E-F0BD7D151CA9Q41489396-BE1A70FB-301E-4453-B0FE-8553A72F17CDQ47598844-D0B4072D-A5DE-4D62-AE14-2D4FCDAE66FAQ49517068-D40135DF-D4A0-4C91-888D-45747DC10072Q50630417-911328B7-492E-4647-B13B-AA27F2E04E6DQ52645858-0B22EEAE-D9EF-43E9-8974-EDE623A75D2DQ54956987-08564EC4-74E4-4C6A-9F2D-504FB13CC4FF
P2860
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Effect of adjuvant/neoadjuvant ...... tive metastatic breast cancer.
@en
Effect of adjuvant/neoadjuvant ...... tive metastatic breast cancer.
@nl
type
label
Effect of adjuvant/neoadjuvant ...... tive metastatic breast cancer.
@en
Effect of adjuvant/neoadjuvant ...... tive metastatic breast cancer.
@nl
prefLabel
Effect of adjuvant/neoadjuvant ...... tive metastatic breast cancer.
@en
Effect of adjuvant/neoadjuvant ...... tive metastatic breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Effect of adjuvant/neoadjuvant ...... tive metastatic breast cancer.
@en
P2093
Amal Melhem-Bertrandt
Ankur Varma
Daniel Booser
Elliana Young
Gabriel N Hortobagyi
James L Murray
Kenneth R Hess
Kimberly H Koenig
Priyankana Mishra
Rashmi K Murthy
P2860
P304
P356
10.1002/CNCR.28689
P407
P577
2014-03-26T00:00:00Z